Clinical trial · Interventional
Palliative Care Yields Cancer Wellbeing Support
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to evaluate the effectiveness of a programme for transitional palliative cancer care (Pal-Cycles) in seven countries (the Netherlands, Germany, United Kingdom, Hungary, Poland, Romania and Portugal) and its consequent effects on the number of readmissions into hospital. The main hypothesis for the study is: that fewer people in the intervention arm of the study will require hospital re admission than those having usual care. Participants will be asked to fill in questionnaires regarding their quality of care and quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| A transitional palliative care intervention | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Pal-Cycles Intervention
- description
- The patients in the intervention arm will be exposed to the Pal-Cycles intervention.
- interventionNames
- Procedure: A transitional palliative care intervention
- type
- NO_INTERVENTION
- label
- Care as usual
- description
- The patients included in this intervention will be given care as usual.
Primary outcomes (1)
- measure
- The difference in number of readmissions into hospital between the patients in the intervention arm and controle arm
- timeFrame
- 90 days after the end of the study or after death.
- description
- The primary outcome of this research project will be the difference between the readmission rate from the control group and the intervention group. This was chosen based on the presumption that if the communication between healthcare professionals improves, the transition to home will be better and patients will be less likely to require hospital care. Another advantage is that it is a feasible and often well documented outcome measure which can be retrieved across multiple sites in multiple countries. A second advantage especially relevant for studies concerned with palliative care patients is that it can be measured early, as many patients die (of unrelated causes) during the study. By measuring early measurement compliance can be ensured.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 years or above * Patients diagnosed with advanced cancer * Patients that are expected to develop or already may have palliative care needs * Patients who are in transition from curative (hospital) to palliative care (community care) Exclusion Criteria: * People with cancer unable or unwilling to provide consent to participate in the study
References
Publications (1)
- DERIVEDHooley R, Payne S, Brunsch H, Surges SM, Mosoiu D, Hurducas F, Hernandez-Marrero P, Pereira SM, Csikos A, Pozsgai E, Leppert W, Forycka-Ast M, van den Brand P, Hasselaar J, Preston N. Adapting a palliative care intervention for people with advanced cancer across seven European countries: the Pal-Cycles intervention. BMC Palliat Care. 2026 Jun 12;25(1):181. doi: 10.1186/s12904-026-02105-0. PMID 42332712